Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

Right arrow Help viewing high resolution images
Right arrow Return to article

Please click here to obtain permission to reproduce this image.

Click on image to view larger version.


Figure 2


Figure 2 Kaplan-Meier Estimates of Primary End Point With Perindopril and Placebo According to Baseline eGFR

Kaplan-Meier estimates of the primary end point with perindopril and placebo for different estimated glomerular filtration rates (eGFR) during follow-up (days). The black line corresponds to patients with an eGFR <75 using placebo, and the dotted black line corresponds to patients with an eGFR <75 using perindopril. The red line corresponds to patients with an eGFR ≥75 using placebo, and the dotted red line corresponds to patients with an eGFR ≥75 using perindopril. The X-axis represents the follow-up time in days. The Y-axis represents the risk of the primary end point. AMI = acute myocardial infarction.





Right arrow Return to article

 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement